IsoRay Announces Fourth Quarter Fiscal 2017 Revenue of $1.37 Million, 22% Fourth Quarter-over-Fourth Quarter Increase

Mr. LaVoy continued, "In other cancers, a growing number of leading institutions are performing brain brachytherapy with Cesium-131. There are multiple publications from Weill Cornell Medical College that demonstrate high rates of brain cancer control when Cesium-131 brachytherapy is combined with surgery. And IsoRay's collaboration with GammaTile LLC to develop and commercialize a custom delivery system is in development with a filing for FDA clearance and reimbursement code assignment in process. In gynecological cancers, a new study was recently accepted for publication in the highly respected International Journal of Radiation Oncology, Biology, Physics (the "Red Journal") on Cesium-131's use in recurrent pelvic malignancies. The study found that the use of Cesium-131 has the ability to control local disease, avoid radical surgery, and provide an improved quality of life for these patients."

"IsoRay is in a unique position as the only manufacturer in the world of Cesium-131, which we believe is the 'next' generation brachytherapy isotope that delivers a faster, more consistent treatment. The combination of improvement in IsoRay's strategic focus and execution, as seen in our fourth quarter results, supported by the growing evidence of Cesium-131's efficacy in treating multiple types of cancers, gives us confidence in our outlook for growth in fiscal 2018 and beyond," concluded Mr. LaVoy.

About IsoRay, Inc.

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Join us on Facebook/IsoRay. Follow us on Twitter @IsoRay.

Safe Harbor Statement

Statements in this news release about IsoRay's future expectations, including: the advantages of our products and their delivery systems, whether interest in and use of our products will increase or continue, whether the new marketing strategy will increase sales, whether the changes to the sales staff will result in increased sales, whether the additional resources being added to IsoRay's online presence will increase patient or clinician engagement and interest, whether use of Cesium-131 in non-prostate applications will increase revenue, whether we obtain and the timing of obtaining our FDA application for 510(k) clearance and favorable reimbursement codes, our ongoing relationship with GammaTile LLC, whether further automation of production processes will be completed or will result in lower costs, whether revenue will increase and costs decrease in the upcoming quarters, the positive industry data fueling renewed interest in brachytherapy, strong patient results, the perception by patients of quality of life outcomes, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of past studies, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, patient results achieved when our products are used for the treatment of cancers and malignant diseases, successful completion of future research and development activities, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, continued compliance with ISO standards, the success of our sales and marketing efforts, changes in reimbursement rates, the procedures and regulatory requirements mandated by the FDA for 510(k) approval and reimbursement codes, agreements we ultimately negotiate with third parties related to distribution of GammaTile products, changes in laws and regulations applicable to our products, the scheduling of physicians who either delay or do not schedule patients in periods  anticipated, the use of competitors' products in lieu of our products, less favorable reimbursement rates than anticipated for each of our products, and other risks detailed from time to time in IsoRay's reports filed with the SEC. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

IsoRay, Inc. and Subsidiaries
Consolidated Balance Sheets
(In thousands, except shares)
	June 30,		June 30,
	2017		2016
ASSETS
Current assets:
Cash and cash equivalents	$            5,932		$          10,139
Certificates of deposit (Note 3)	3,039		2,247
Accounts receivable, net of allowance for doubtful accounts of $26 and $30, respectively	726		605
Inventory	323		334
Prepaid expenses and other current assets	271		304
Total current assets	10,291		13,629
Property and equipment, net	1,054		577
Certificates of deposit, non-current (Note 3)	-		2,973
Restricted cash	181		181
Inventory, non-current	513		591
Other assets, net of accumulated amortization	230		151
Total assets	$          12,269		$          18,102
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued expenses	$               630		$               612
Accrued protocol expense	75		122
Accrued radioactive waste disposal	125		177
Accrued payroll and related taxes	138		72
Accrued vacation	138		111
Total current liabilities	1,106		1,094
Long-term liabilities:
Warrant derivative liability	-		27
Asset retirement obligation	561		580
Total liabilities	1,667		1,701
Commitments and contingencies  (Note 15)
Shareholders' equity:
Preferred stock, $.001 par value; 7,001,671 shares authorized:
Series A: 1,000,000 shares allocated; no shares issued and outstanding	-		-
Series B: 5,000,000 shares allocated; 59,065 shares issued and outstanding	-		- Werbung Mehr Nachrichten zur Perspective Therapeutics Inc Aktie kostenlos abonnieren E-Mail-Adresse Bitte überprüfe deine die E-Mail-Adresse. Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1 Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News 24.04.24 - PR Newswire Fidelity European Trust Plc - Monthly Factsheet 24.04.24 - PR Newswire Fidelity Emerging Markets Ltd - Monthly Factsheet 24.04.24 - PR Newswire Oscillate Plc - Holding(s) in Company Solarboom 2024:    5 Gründe die für diese Aktie sprechen… weiterlesen» Anzeige wo-site-teaser-box-16746_site-teaser-box_2024-04-24_08%253A00%253A00_2024-04-25_09%253A00%253A59